Identifying splicing-related neoantigens in gliomas opens new avenues for immunotherapy, enhancing treatment strategies for ...

For female patients with glioma, pregnancy after receiving a diagnosis of glioma is associated with worse progression-free ...

Vorasidenib is an oral medication designed specifically to target low-grade gliomas that have mutations in the IDH1 or IDH2 genes. These mutations are found in the majority of low-grade gliomas and ...

In the neuro-oncology field, neuroradiological research has recently explored the potential of non-invasively predicting the molecular phenotype of primary brain neoplasms, particularly gliomas, based ...

Fractionated reirradiation is safe and feasible, suggesting higher reirradiation dose may be feasible in patients with ...

Geddy has lived a big life for a little dog. As a puppy, the tiny terrier mix was abandoned in Mississippi during a ...

Genomic and transcriptomic analyses of gliomas have revealed significant inter and intratumoral heterogeneity and insights into their molecular pathogenesis. Moreover, recent evidence suggests that ...

Temozolomide with radiation therapy improved 5- and 10-year OS for patients with grade 2 gliomas. The addition of temozolomide did not extend PFS. The addition of temozolomide to radiation therapy ...

A brain tumour reporting system improves the monitoring and treatment of primary brain tumours with high reliability.

Many low-grade gliomas have something known as an IDH-mutation. These mutations can help promote tumor growth. A drug called vorasidenib is an exciting new targeted treatment option for low-grade ...